Wheeler Bio, a contract development and biomanufacturing organization based in the United States, has announced a significant partnership with MindImmune Therapeutics to support the development of its lead program, MITI-101, aimed at preventing Alzheimer’s disease. This agreement, revealed on September 17, 2025, will allow Wheeler Bio to utilize its ModularCMC platform for integrated process development and cGMP drug substance manufacturing.
Advancing Alzheimer’s Research
The collaboration focuses on advancing MITI-101, a monoclonal antibody designed to block the recruitment of CD11c+ immune cells from the bloodstream into the brain. These immune cells are believed to contribute to the neuroinflammation associated with Alzheimer’s disease and other neurodegenerative disorders. The initiative represents a pioneering approach to target the underlying mechanisms of neuroinflammation, which has been a significant hurdle in Alzheimer’s treatment.
Patrick Lucy, President and CEO of Wheeler Bio, expressed enthusiasm about the partnership, highlighting the urgent need for effective treatments in Alzheimer’s care. “We are thrilled to establish this partnership with MindImmune to advance this promising therapeutic focused on a disease where there is significant unmet medical need,” he stated.
MindImmune Therapeutics, which operates out of the University of Rhode Island, has positioned itself as a leader in addressing neuroinflammation. Stevin Zorn, President and CEO of the company, noted, “MITI-101 represents a first-in-class strategy to stop harmful innate immune cells from driving brain inflammation in Alzheimer’s.” He emphasized that the collaboration with Wheeler Bio would expedite the transition of this innovative science into clinical settings, offering hope to those affected by debilitating diseases.
High-Quality Biomanufacturing
The ModularCMC platform from Wheeler Bio is designed to streamline the development process, ensuring agility and scalability from initial discovery through to clinical study initiation. This platform is particularly tailored for antibody-based modalities, facilitating rapid translation of drug candidates into clinical trials.
Wheeler Bio has a proven track record, having worked on over 1,400 unique molecules, demonstrating its expertise in biomanufacturing. Their approach emphasizes transparency and scientific rigor, which are critical components when navigating the complexities of drug development.
The partnership between Wheeler Bio and MindImmune builds upon MindImmune’s earlier collaboration with Alloy Therapeutics during the discovery phase. By leveraging the combined strengths of these organizations, the partnership is set to optimize the economic benefits of their joint efforts.
As the global health community continues to seek effective solutions to Alzheimer’s disease, the focus on neuroinflammation and its role in disease progression becomes increasingly vital. This collaboration not only enhances research capabilities but also aligns with the urgent need for new therapeutic options in a field marked by significant challenges.
Wheeler Bio’s mission remains clear: to accelerate the translation of drug discoveries into tangible clinical impacts, ultimately benefiting patients and their families facing neurodegenerative diseases.
For more information on this partnership and its implications for Alzheimer’s research, visit the official websites of Wheeler Bio and MindImmune Therapeutics.